← Back to Search

Intraocular Lens

New Lens Implant for Cataract Surgery

N/A

Waitlist Available

Research Sponsored by Alcon Research

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Planned cataract surgery (both eyes)

Be older than 18 years old

Must not have

Women of childbearing potential if currently pregnant, intend to become pregnant during the study, or are breastfeeding

Timeline

Screening 3 weeks

Treatment Varies

Follow Up month 2 postoperative

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to see if a new type of lens, called Clareon™ PanOptix™ Pro Trifocal Intraocular Lens, is both safe and works well compared to the standard Clare

Who is the study for?

This trial is for adults with cataracts and presbyopia who need both eyes operated on, have less than 1.00 diopter of corneal astigmatism in each eye, can attend all visits, and aren't pregnant or breastfeeding. People with certain eye conditions or those wanting monovision correction cannot join.

What is being tested?

The study compares two types of trifocal lenses implanted during cataract surgery: Clareon PanOptix Pro IOL versus the standard Clareon PanOptix IOL to see which is safer and more effective.

What are the potential side effects?

Potential side effects from lens implantation may include visual disturbances like glare, halos around lights, difficulty driving at night, blurry vision, or eye discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am scheduled for cataract surgery on both eyes.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am not pregnant, do not plan to become pregnant during the study, and am not breastfeeding.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ month 2 postoperative

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~month 2 postoperative

This trial's timeline: 3 weeks for screening, Varies for treatment, and month 2 postoperative for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Mean Monocular Photopic Best Corrected Distance Visual Acuity (BCDVA)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: CPO Pro IOLExperimental Treatment3 Interventions

CPO Pro IOL implanted in the first eye, as randomized. The fellow eye will receive CPO IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.

Group II: CPO IOLActive Control3 Interventions

CPO IOL implanted in the first eye, as randomized. The fellow eye will receive CPO Pro IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cataract surgery

2015

N/A

~3790

0 / 2Eligibility criteria met